Cell & Gene Therapy Cold Chain Logistics Market to Grow with a CAGR of 6.19% through 2028
Rising Clinical Trials Approvals are expected to drive
the Germany Cell & Gene Therapy Cold Chain Logistics Market growth in the
forecast period, 2024-2028.
According to TechSci Research report, “Cell &
Gene Therapy Cold Chain Logistics Market – Germany Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Germany Cell
& Gene Therapy Cold Chain Logistics Market stood at USD 107.51 million in
2022 and is anticipated to grow with a CAGR of 13.87% in the forecast period,
2024-2028. Germany has been at the forefront of cell and gene therapy research
and development. The country's renowned pharmaceutical and biotechnology
industry has been instrumental in driving innovation in this field. As more
breakthrough therapies are developed, the need for a robust cold chain
logistics system becomes increasingly evident. These therapies often involve
fragile and temperature-sensitive materials, making specialized logistics
essential to maintain their efficacy. Germany is witnessing a surge in clinical
trials and approvals for cell and gene therapies. With an emphasis on precision
medicine and personalized treatments, the demand for secure transportation of
patient-specific therapies is on the rise. The cold chain logistics market is
benefiting from this trend, as it must provide specialized services to ensure
the safe delivery of these therapies from manufacturing facilities to
healthcare providers.
The rapid evolution of technology is driving
innovation in the cold chain logistics market. Advanced temperature monitoring
systems, IoT (Internet of Things) solutions, and data analytics are becoming
integral to ensuring the integrity of cell and gene therapy products during
transportation. These technologies are not only improving the safety and
efficiency of logistics but also reducing costs, making them more attractive to
industry players.
Regulatory bodies in Germany, such as the Federal
Institute for Drugs and Medical Devices (BfArM), and the European Medicines
Agency (EMA), have established strict guidelines for the transportation and
storage of cell and gene therapy products. Compliance with these regulations is
non-negotiable, and logistics providers must adhere to them to ensure product
safety and efficacy. This emphasis on compliance has boosted the demand for
specialized cold chain logistics services. Both public and private investments
are flowing into the cell and gene therapy sector in Germany. Funding is being
directed towards research, development, and the expansion of manufacturing
facilities. With more therapies entering the pipeline, the demand for cold
chain logistics is rising in tandem. Investors recognize the potential of this
market and are actively supporting its growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Germany
Cell & Gene Therapy Cold Chain Logistics Market.”
Germany has emerged as a popular destination for
dental tourism, attracting patients from across Europe and beyond. The
country's high-quality dental care, well-trained professionals, and advanced
dental facilities have made it an attractive choice for individuals seeking
dental treatments. Dental tourism has resulted in a higher influx of patients,
leading to increased demand for Cell & Gene Therapy Cold Chain Logistics in
German dental clinics and hospitals.
The Germany Cell & Gene Therapy Cold Chain
Logistics Market is segmented into Component, Services Offered, Mode of
Transportation, Holding
Temperature Range, End User,
Regional
Distribution, And Company.
Based on the Component, Cryogenic Shippers emerged as
the dominant segment in the North America market for Germany Cell & Gene
Therapy Cold Chain Logistics Market in 2022. irst cell and gene therapies often
involve the transportation of extremely fragile and temperature-sensitive
biological materials, such as living cells, viral vectors, or nucleic acids.
These materials must be stored and transported at ultra-low temperatures,
typically in the range of -80°C to -196°C, to maintain their stability and
efficacy. Cryogenic shippers, which utilize liquid nitrogen or other cryogenic
agents, provide the necessary extreme cold conditions for the secure transport
of these therapies. the stringent regulatory guidelines enforced by entities
like the Federal Institute for Drugs and Medical Devices (BfArM) and the
European Medicines Agency (EMA) necessitate the use of highly reliable and
validated temperature-controlled systems. Cryogenic shippers have proven
themselves as reliable and well-established solutions that meet the stringent
temperature control requirements set forth by these regulatory bodies.
Based on the Holding Temperature Range, the Cryogenic
segment emerged as the dominant player in the North America market for Germany
Cell & Gene Therapy Cold Chain Logistics Market in 2022. First and foremost, cell and gene therapies often
involve the transport and storage of extremely delicate and
temperature-sensitive biological materials, including living cells, viral
vectors, and nucleic acids. These materials require ultra-low temperatures to
maintain their stability and effectiveness, typically within the range of -80°C
to -196°C. Cryogenic holding temperature ranges, which utilize liquid nitrogen
or other cryogenic agents, provide the ideal conditions for ensuring the safe
preservation of these therapies throughout the supply chain.Additionally, the
stringent regulatory requirements imposed by entities such as the Federal
Institute for Drugs and Medical Devices (BfArM) and the European Medicines
Agency (EMA) demand the highest level of temperature control and stability.
Cryogenic storage solutions have demonstrated their reliability in maintaining
these stringent temperature standards, making them a preferred choice for
complying with regulatory guidelines.The rising number of clinical trials and
approvals for cell and gene therapies in Germany further accentuates the
importance of cryogenic holding temperature ranges. These trials often involve
patient-specific therapies that require precise temperature control and
stability to ensure their safety and efficacy. Cryogenic systems offer the most
secure and dependable means of achieving these critical temperature conditions.
Based on the Services Offered, the Transportation
segment emerged as the dominant player in the North America market for Germany
Cell & Gene Therapy Cold Chain Logistics Market in 2022. cell and gene
therapies often involve the transportation of highly delicate and
temperature-sensitive biological materials, such as living cells, viral
vectors, and nucleic acids. Maintaining the required temperature conditions
throughout the transportation process is critical to preserving the integrity
and efficacy of these therapies. Transportation services are at the forefront
of achieving this, as they are responsible for physically moving these products
from manufacturing facilities to research institutions, healthcare providers,
or directly to patients. the Germany Cell & Gene Therapy Cold Chain
Logistics Market has experienced a surge in clinical trials and approvals for
these innovative therapies. Clinical trials frequently require the
transportation of patient-specific therapies, demanding precise, secure, and
timely delivery. Transportation services offer specialized expertise, equipped
vehicles, and temperature-controlled containers that ensure the therapies
arrive in pristine condition.
Western region emerged as the dominant player in the
Germany Cell & Gene Therapy Cold Chain Logistics Market in 2022, holding
the largest market share. Western Germany is home to major cities such as
Frankfurt, Düsseldorf, and Cologne, which have established themselves as
biotech and pharmaceutical hubs. These cities host numerous research
institutions, pharmaceutical companies, and biotechnology firms engaged in
cutting-edge cell and gene therapy research and development. The concentration
of these organizations in the Western region results in a higher demand for
logistics services to support their activities. The Western region boasts a
strong and diverse economy, making it a favorable location for investment and
innovation in the life sciences sector. The economic strength of this region
enables it to attract significant investments in research and clinical trials
related to cell and gene therapies. As these therapies progress, the demand for
cold chain logistics services for transportation and storage naturally surges
Major companies operating in Germany Cell & Gene
Therapy Cold Chain Logistics Market are:
- AmerisourceBergen Corporation (World Courier)
- United Parcel Service (Marken)
- Catalent, Inc.
- BioLife Solutions, Inc.
- Cryoport, Inc.
- Atelerix Ltd.
- Biostor Ltd.
- Thermo Fisher Scientific Inc.
- Life Science Group Ltd (LSG)
- Yourway Biopharma Services Company
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Germany
Cell & Gene Therapy Cold Chain Logistics Market is poised for significant
growth in the coming years. Anticipated advancements in cell and gene
therapies, along with a robust clinical trials pipeline, will continue to drive
demand for precise and temperature-controlled logistics services. Germany's
position as a leader in biotechnology and pharmaceutical research further
reinforces its role as a key player in the development and distribution of
these innovative therapies.The rising number of clinical trials and approvals
by regulatory bodies such as the Federal Institute for Drugs and Medical
Devices (BfArM) and the European Medicines Agency (EMA) underscores the
industry's increasing recognition and acceptance. As these therapies transition
from experimental to mainstream treatments, the importance of secure and
compliant cold chain logistics becomes even more evident.” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Germany Cell & Gene Therapy Cold Chain
Logistics Market Segmented By Component (Cryogenic Shippers, Cryogenic Storage
Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and
Storage Medium, Cryogenic Packout Kits Others {Shipment Containers, Reusable
Boxes, etc.}), By Services Offered (Transportation, Storage, Packaging) , By
Mode of Transportation (Air, Ground, Water) , By Holding Temperature Range (Cryogenic,
Refrigerated, Ambient, Others {Deep Freezers, Dry Ice, etc.}) , By End User (Pharmaceutical
& Biotechnology Companies, Academic & Research Institutes, Others)
Region and Competition, Opportunity, and Forecast, 2018-2028”, has evaluated
the future growth potential of Germany Cell & Gene Therapy Cold Chain
Logistics Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Germany Cell & Gene
Therapy Cold Chain Logistics Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com